Cronos Group: Canaccord Reiterates Sell Rating Follow Q4 2021 Results

Yesterday, Cronos Group (TSX: CRON) reported their fourth-quarter and full-year financial results. The company reported revenues of $25.8 million for the quarter, of which $18.8 million came from cannabis flower revenue, $3.8 million came from extracts, and $3.1 million came from their US based CBD business. The company saw its gross margins come in at 8%, and an adjusted EBITDA of ($27.4) million for the quarter.

For the year end, the company reported full year revenues of $74.4 million, up 59% year over year. Of that $74.4 million, $55.2 million came from cannabis flower, $8.8 million from extracts, and $9.8 million from their CBD business. The company reported full-year gross margins of (24%) and an adjusted EBITDA of ($160.5) million.

Cronos currently has 12 analysts covering the stock with an average 12-month price target of C$6.39, which represents a 46% upside to the current stock price. Out of the 12 analysts, 2 have buy ratings, 8 have hold ratings, 1 analyst has a sell rating and another analyst has a strong sell rating on Cronos’ stock. The street high sits at C$12, which represents a 175% upside to the stock price.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

In Canaccord’s fourth quarter review note, they reiterate their sell rating on the name and C$4.25 12-month price target, saying that the earnings somewhat surprised them with better than expected numbers. Though they say that the numbers got overshadowed by a material impairment of its legacy Peace Naturals production and cultivate site.

On the quarterly results, Canaccord was forecasting that revenue would be $23.5 million with a gross margin of $941 thousand. This minor beat comes as Cronos’ CBD business is seeing a rebound in sales from the previous quarter but still below last year’s sales. The company also reported another quarter of better than expected sequential cannabis sales, with the company seeing its cannabis revenue grow by 24% quarter over quarter. Canaccord now believes that Cronos has a sub 5% market share in branded adult-use cannabis sales.

Cronos also notably reported its first positive gross margin percentage in over two years, with the company continuing to right-size its operations. Canaccord believes that the company is turning a new leaf. The biggest thing to note from the company’s income statement is the larger $120 million impairment on its Peace Naturals production and cultivation facility. This comes after it reported a $236 million impairment last quarter.

Below you can see Canaccord’s updated fiscal full year 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Goliath Extends Golden Gate Lode 130 Metres With 13.45 g/t Gold Equivalent Over 4.85 Metres

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Related News

Hexo Sees Revenues Decline 31% To $22.7 Million In Q3 2021

Hexo Corp (TSX: HEXO) (NYSE: HEXO) this morning reported a doozy of a quarter. The...

Monday, June 14, 2021, 08:40:27 AM

GFL Environmental: BMO Lifts Target To US$42 After Asset Divesture

At the start of the month, GFL Environmental Inc. (TSX: GFL) announced that they completed...

Friday, October 15, 2021, 11:34:00 AM

BMO Reiterates $10 Price Target On Kinross Gold Following Russian Asset Sale

On April 5th, Kinross Gold (TSX: K) announced the sale of its Russian assets, with...

Saturday, April 9, 2022, 03:03:00 PM

Verano: Analysts Expect Q3 Revenues Of $219.7 Million

Verano Holdings (CSE: VRNO) announced that they will be reporting their third quarter financials before...

Monday, November 15, 2021, 10:10:00 AM

Hycroft Mining Cash Infusion Not Near Enough To Re-Enter Production, Says BMO

This week, Hycroft Mining (NASDAQ: HYMC), a busted SPAC mining company taken public by Mudrick...

Thursday, March 17, 2022, 04:52:00 PM